Security key
29337E102
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)
CUSIP: 29337E102
Q1 2023 13F Holders as of 31 Mar 2023
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 59,773,132
- Total 13F shares
- 33,557,749
- Share change
- +33,557,749
- Total reported value
- $734,910,999
- Put/Call ratio
- 0.14%
- Price per share
- $21.90
- Number of holders
- 44
- Value change
- +$734,911,000
- Number of buys
- 44
Report period
Q1 2023
Institutions
44
Top holders
10
ELVN full security history
Newer quarter: Q2 2023
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29337E102
Recent filing periods:
Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| David P. Bonita |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,207,568
mixed-class rows
|
$63,552,894 | — | 02 Jun 2022 | |
| New Enterprise Associates 14, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,611,050
|
$39,518,242 | — | 05 Apr 2022 | |
| RA CAPITAL MANAGEMENT, L.P. |
3/4/5
|
Former 10% owner |
—
class O/S missing
|
2,122,465
|
$32,123,508 | — | 23 Feb 2023 | |
| Braden M. Leonard |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,997,774
|
$30,236,309 | — | 03 Jan 2023 | |
| Commodore Capital LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,448,640
|
$21,925,166 | — | 23 Feb 2023 | |
| Andrew J. Schwab |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
27,567
|
— | — | 23 Feb 2023 | |
| Mark Chin |
3/4/5
|
Director |
—
mixed-class rows
|
2,352,572
mixed-class rows
|
$35,477,530 | — | 02 Jun 2022 | |
| Barbara Dalton |
3/4/5
|
Director |
—
mixed-class rows
|
1,566,222
mixed-class rows
|
$23,576,122 | — | 02 Jun 2022 | |
| Carl Goldfischer |
3/4/5
|
Director |
—
mixed-class rows
|
711,880
mixed-class rows
|
$10,645,656 | — | 02 Jun 2022 | |
| David M. Mott |
3/4/5
|
Director |
—
mixed-class rows
|
237,724
mixed-class rows
|
$3,469,305 | — | 02 Jun 2022 | |
| Kenneth Attie |
3/4/5
|
SVP, CMO |
—
mixed-class rows
|
68,200
mixed-class rows
|
$516,104 | — | 28 Jan 2022 | |
| Michael Gray |
3/4/5
|
CFO & COO |
—
class O/S missing
|
27,610
|
$417,877 | — | 22 Feb 2023 | |
| Edward R. Conner |
3/4/5
|
Director |
—
class O/S missing
|
8,500
|
— | — | 02 Jun 2022 | |
| Laura A. Williams |
3/4/5
|
Director |
—
class O/S missing
|
8,500
|
— | — | 02 Jun 2022 | |
| Sara M. Nayeem |
3/4/5
|
Director |
—
class O/S missing
|
7,728
|
— | — | 29 Jun 2021 |
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q1 2023
As of 31 Mar 2023,
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,557,749 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, 5AM Venture Management, LLC, FMR LLC, CITADEL ADVISORS LLC, VR Adviser, LLC, RA CAPITAL MANAGEMENT, L.P., Cormorant Asset Management, LP, Fairmount Funds Management LLC, COMMODORE CAPITAL LP, and Frazier Life Sciences Management, L.P..
This page lists
44
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2023 vs Q4 2025 Across Filers
Q4 2025 holders
125
Q1 2023 holders
44
Holder diff
-81
| Investor | Q4 2025 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.